OBT and Boehringer Ingelheim Enter Collaboration
News Apr 29, 2013
Oxford BioTherapeutics (OBT) and Boehringer Ingelheim (BI) have announced a new alliance focused on the discovery of novel cancer antibody targets that OBT will identify with the help of its OGAP® discovery platform.
Under the collaboration OBT will validate certain targets it has discovered that are compatible with targeting by various antibody drug formats across a range of cancer indications.
Following completion of these activities, BI will have the exclusive right to develop and commercialize antibody products for selected programs.
OBT will receive an undisclosed upfront payment and FTE funding for its activities under the collaboration, and will be eligible for certain milestone payments upon the achievement of specified discovery, development and commercialization milestones, as well as royalties on sales of any resulting products.
Christian Rohlff, CEO of OBT, commented: “Selecting the right target is fundamental for the successful development of a first-in-class antibody product drug and we are delighted to collaborate with a company of the calibre of BI in this exciting area of cancer antibody development.”
Tight junctions are multi-protein complexes that serve as barriers in epithelial tissues such as the skin or lining of the gut. Loss of a specific tight junction barrier protein, claudin 18, occurs in the majority of gastric cancer patients and is correlated with poor prognosis in patients with advanced gastric cancer.READ MORE